Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Lexicon Pharmaceuticals (LXRX) Deferred Taxes (2017)

Lexicon Pharmaceuticals has reported Deferred Taxes over the past 1 years, most recently at -$4.0 million for Q4 2017.

Quarterly Deferred Taxes changed N/A to -$4.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$4.0 million through Sep 2018, up 53.66% year-over-year, with the annual reading at -$6.0 million for FY2019, N/A changed from the prior year.
Deferred Taxes was -$4.0 million for Q4 2017 at Lexicon Pharmaceuticals, up from -$8.7 million in the prior quarter.
Over five years, Deferred Taxes peaked at -$4.0 million in Q4 2017 and troughed at -$8.7 million in Q1 2017.